Abstract: An awning arm assembly is provided that includes inner and outer arms. A joint is provided that has an axle, e.g., any structure about which rotation can be provided coupled with one of the inner arm and the outer arm and a hollow body disposed about the axle. The hollow-body is coupled with the other of the inner arm and the outer arm. The hollow body is coupled with the axle such that when the outer arm moves relative to the inner arm the angle between the hollow body and the axle (and thereby the inner and outer arms) is adjusted.

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

Abstract: An umbrella hub is provided that comprises an inner portion, an outer periphery, a lower portion and an upper portion. A plurality of vertical grooves is disposed in the outer periphery and is configured to receive umbrella ribs or struts. A plurality of grooves extends transverse to the vertical grooves. A retention member is disposed in each of the transverse grooves. A first configuration of the hub permits deflection of the retention member such that a transverse pin coupled with the umbrella ribs or struts can be inserted into the transverse groove in which the retention member is disposed. A second configuration of the hub prevents deflection of the retention member such that inadvertent withdrawal of the pin from the transverse groove in which the retention member is disposed is prevented.

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (I) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

Abstract: The present invention relates to a selective hydrogenation catalyst for an unsaturated compound. The supported catalyst contains at least one Group VIB non-noble metal oxide and at least one Group VIII non-noble metal oxide deposited on a carrier; and the catalyst has an optimized acid distribution on the surface of the catalyst, and more preferably has an optimized Group VIII/VIB metal ratio and a Group VIII non-noble metal density per unit of catalyst surface area. Using the catalyst of the present invention can have the following advantages: the weight increase of light sulphides in an unsaturated compound or a mixture containing unsaturated compounds, the hydrogenation of a polyunsaturated compound, the isomerization of a monounsaturated compound, high operation flexibility and a significant improvement in the effects of a hydrogenation treatment.

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (I) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

Abstract: The present invention relates to a selective hydrogenation catalyst for an unsaturated compound. The supported catalyst contains at least one Group VIB non-noble metal oxide and at least one Group VIII non-noble metal oxide deposited on a carrier; and the catalyst has an optimized acid distribution on the surface of the catalyst, and more preferably has an optimized Group VIII/VIB metal ratio and a Group VIII non-noble metal density per unit of catalyst surface area. Using the catalyst of the present invention can have the following advantages: the weight increase of light sulphides in an unsaturated compound or a mixture containing unsaturated compounds, the hydrogenation of a polyunsaturated compound, the isomerization of a monounsaturated compound, high operation flexibility and a significant improvement in the effects of a hydrogenation treatment.

Abstract: A carbon-separated ultrafine nano WC material and a method of preparing the same as well as a use thereof, wherein the carbon-separated ultrafine nano WC material is prepared by a method comprising the following steps: (1) a solution of a tungsten source in deionized water is added into a solution prepared from ethanol, concentrated ammonia and a surfactant, wherein the tungsten source is ammonium metatungstate, sodium tungstate or tungsten chloride, and the surfactant is sodium dodecyl benzene sulfonate, ammonium hexadecyl trimethyl bromide or P123; resorcinol is added after intimate agitation; formaldehyde is then added after intimate agitation; and then agitation at room temperature is continued for 8-28 h to produce a mixed solution; (2) the mixed solution is subjected to hydrothermal reaction, and a mixed polymer is obtained after drying; and (3) the mixed polymer is carburized at a high temperature in CO atmosphere to produce the carbon-separated ultrafine nano WC material.

Abstract: Disclosed are WC/CNT, WC/CNT/Pt composite material and preparation process therefor and use thereof. The WC/CNT/Pt composite material comprises mesoporous spherical tungsten carbide with diameter of 1-5 microns, carbon nanotubes and platinum nanoparticles, with the carbon nanotubes growing on the surface of the mesoporous spherical tungsten carbide and expanding outward, and the platinum nanoparticles growing on the surfaces of the mesoporous spherical tungsten carbide and carbon nanotubes. The WC/CNT composite material comprises mesoporous spherical tungsten carbide with diameter of 1-5 microns, and carbon nanotubes growing on the surface of the mesoporous spherical tungsten carbide and expanding outward. The WC/CNT/Pt composite material can be used as an electro-catalyst in a methanol flue battery, significantly improving the catalytic conversion rate and the service life of the catalyst.

Abstract: Disclosed are WC/CNT, WC/CNT/Pt composite material and preparation process therefor and use thereof. The WC/CNT/Pt composite material comprises mesoporous spherical tungsten carbide with diameter of 1-5 microns, carbon nanotubes and platinum nanoparticles, with the carbon nanotubes growing on the surface of the mesoporous spherical tungsten carbide and expanding outward, and the platinum nanoparticles growing on the surfaces of the mesoporous spherical tungsten carbide and carbon nanotubes. The WC/CNT composite material comprises mesoporous spherical tungsten carbide with diameter of 1-5 microns, and carbon nanotubes growing on the surface of the mesoporous spherical tungsten carbide and expanding outward. The WC/CNT/Pt composite material can be used as an electro-catalyst in a methanol flue battery, significantly improving the catalytic conversion rate and the service life of the catalyst.

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).

Abstract: The present invention provides processes and intermediates useful in the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, a serotonin (5-HT) receptor agonist that is useful in the treatment or prophylaxis of, for example, central nervous system disorders, such as obesity.

Abstract: The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).